Argenx Se
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Argenx Se
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
/ 
Frequently asked questions
To buy Argenx Se stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Argenx Se by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Argenx Se is ARGX:xbru. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Argenx Se has its primary listing on Euronext Brussels. You can trade Argenx Se with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Argenx Se is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Argenx Se as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Argenx Se.